E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
HIV-1 INFECTION |
INFEZIONE DA HIV-1 |
|
E.1.1.1 | Medical condition in easily understood language |
HIV-1 VIRUS INFECTION |
INFEZIONE DA VIRUS HIV-1 |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Virus Diseases [C02] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the virological efficacy at week 48 of once daily doravirine plus
raltegravir dual therapy in HIV-1-infected patients suppressed on ART |
Valutare l'efficacia virologica alla settimana 48 di una dual therapy una volta al giorno con doravirina/raltegravir in pazienti affetti da HIV-1 soppressi e in ART |
|
E.2.2 | Secondary objectives of the trial |
To evaluate over 96 weeks:
• Virological efficacy of the doravirine plus raltegravir dual therapy
• To assess the proportion of patients in therapeutic success up to week
48 and week 96
• Resistance profile in case of virological failure
• Evolution of CD4 and CD8 T-cells, and CD4/CD8 ratio
• Clinical and biological tolerability of the doravirine plus raltegravir dual
therapy
• Quality of life questionnaire
• Observance questionnaire
• Evolution of HIV-reservoir (Whole blood will be collected at D0, W48 and
W96)
|
Valutare alla settimana 96:
- L’Efficacia virologica della dual therapy con doravirina/raltegravir
- La percentuale di pazienti con successo terapeutico alla settimana 48 e settimana 96
- Il Profilo di resistenza in caso di fallimento virologico
- l’Evoluzione delle cellule T CD4 e CD8 e il rapporto CD4/CD8
- la Tollerabilità clinica e biologica della dual therapy doravirina/raltegravir
- il Questionario sulla qualità della vita
- il Questionario di osservazione
- l’Evoluzione del serbatoio dell'HIV (il sangue intero sarà raccolto ai seguenti time-points D0, W48 e W96)
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Age ≥ 18 years
• Patients with HIV-1 documented infection
• CD4 ≥ 200/mm3
• On stable combined ART regimen with at least 2 drugs for at least 6
months
• HIV-RNA plasma VL ≤ 50 copies/mL during the last 12 months prior to
screening visit (W-6/W-4), documented by at least 2 time-points with no
more than one blip (defined as one HIV-RNA plasma VL between 51 and
200 copies/mL followed by one HIV-RNA plasma VL ≤ 50 copies/mL)
• Naive to doravirine
• Absence of resistance to doravirine* and/or raltegravir**(see list mutations
below)
- on all HIV-genotypes with available RT and integrase gene sequences
allowing resistance interpretation in case of previous virological failure
- or on DNA genotype performed at screening if HIV genotype is not
available in case of prior virological failure.
• Signed informed consent form.
• Patient affiliated to a social insurance regimen. For French patients only:
subject enrolled in or a beneficiary of a Social Security programme (State
Medical Aid or AME is not a Social Security programme).
*Mutations associated to doravirine resistance are: V106A/M, Y188L, G190E/S,
M230L, F227C, at least 2 among: A98G, L100I, K101E, V106I,
E138K, Y181C/V, G190A or H221Y
**Mutations associated to raltegravir resistance are: T66A/K, E92Q, G118R,
F121Y, G140A/S Y143A/C/G/H/R/S, Q148E/G/H/K/R, V151L, N155H/S/T,
E157Q, S230R, R263K, L74 F/I + V75I |
- Età ≥ 18 anni
- Pazienti con infezione da HIV-1 documentata
- CD4 ≥ 200/mm3
- In regime stabile di ART combinata con almeno 2 farmaci per almeno 6 mesi
- Plasma HIV-RNA VL ≤ 50 copie/mL negli ultimi 12 mesi prima di visita di screening (W-6/W-4), documentata da almeno 2 punti temporali con non più di un blip (definito come un plasma HIV-RNA VL tra 51 e 200 copie/ml seguite da un plasma HIV-RNA VL ≤ 50 copie/ml)
- Naive a doravirina
- Assenza di resistenza alla doravirina* e/o al raltegravir**(vedi elenco mutazioni sotto)
- su tutti i genotipi di HIV con disponibilità di sequenze di geni RT e integrase
- o sul genotipo eseguito al momento dello screening se il genotipo dell'HIV non è
disponibile in caso di precedente insuccesso virologico.
- modulo di consenso informato firmato
**Mutations associated to raltegravir resistance are: T66A/K, E92Q, G118R,
F121Y, G140A/S Y143A/C/G/H/R/S, Q148E/G/H/K/R, V151L, N155H/S/T,
E157Q, S230R, R263K, L74 F/I + V75I |
|
E.4 | Principal exclusion criteria |
• Absence of RT and INI HIV sequence available (past genotypes or failure
of amplification of DNA at screening)
• HBV co-infection
• Hemoglobin <9 g/dL
• Platelets <80,000/mm3
• Creatinine clearance <60 mL/min (MDRD)
• AST or ALT ≥5N
• Concomitant DAA for anti-HCV therapy
• Any severe concomitant illness
• Any drug with potential drug-drug interaction with doravirine
• Concomitant treatment using interferon, interleukins or any other immunetherapy
or chemotherapy
• Concomitant prophylactic or curative treatment for an opportunistic
infection
• All conditions (use of alcohol, drugs, etc.) judged by the investigator to
possibly interfere with trial protocol compliance, adherence and/or trial
treatment tolerance
• Subjects under "sauvegarde de justice" (judicial protection due to
temporarily and slightly diminished mental or physical faculties), or under
legal guardianship
• Subjects participating in another clinical trial evaluating different therapies
and including an exclusion period that is still in force during the screening
phase
• Pregnant women or breastfeeding women |
- Assenza di una sequenza genotipica di RT e INI disponibile
- Coinfezione HBV
- Emoglobina <9 g/dL
- Piastrine <80.000/mm3
- Clearance della creatinina <60 mL/min (MDRD)
- AST o ALT ≥5N
- concomitante DAA per la terapia anti-HCV
- Qualsiasi grave malattia concomitante
- Qualsiasi farmaco con potenziale interazione con la doravirina
- Trattamento concomitante con interferone, interleuchine o qualsiasi altra immunoterapia
o chemioterapia
- Trattamento profilattico o curativo concomitante per infezione opportunistica
- Tutte le condizioni (uso di alcol, droghe, ecc.) giudicate dall'investigatore come interferenti con il trattamento del protocollo
- Soggetti sotto tutela giudiziaria
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint is the proportion of patients with
virological failure before or at week 48.
Protocol virological failure is defined as two pVL>50 copies/mL two weeks apart |
Valutare la percentuale di pazienti con fallimento virologico prima o alla settimana 48. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
To evaluate over 96 weeks:
• Proportion of patients maintaining viral suppression (pVL <50 copies/mL,
Snapshot approach)
• Evolution of CD4 and CD8 T-cells, and CD4/CD8 ratio
• Proportion of patients with virological blips (HIV-RNA pVL>50 copies/mL
followed by a second measurement <50 copies/mL)
• Resistance profile in case of protocol defined virological failure (PDVF)
• Proportion of patients with acquired resistance mutation among those with
PDVF
• Frequency of grade 3 and 4 events
• Quality of life assessed by self-questionnaire at screening, D0, W24,
W48, W72, W96
• Observance assessed by self-questionnaire at D0, W24, W48, W96
• Evolution of total cell HIV-DNA in PBMC from D0 to W48 and W96 |
-percentuale di pazienti che mantengono la soppressione virale (pVL<50 copie/mL, approccio istantaneo)
-percentuale di pazienti con blip virologici
-evoluzione delle cellule T CD4 e CD8 e rapporto CD4/CD8
-profilo di resistenza in caso di fallimento virologico definito dal protocollo (PDVF)
-percentuale di pazienti con mutazione di resistenza acquisita tra quelli con PDVF
-frequenza degli avventi avversi di grado 3 e 4
-qualità della vita valutata dall’auto-questionario
-aderenza/osservanza valutata dall’auto-questionario
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 8 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 8 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
LVLP |
ULTIMA VISITA DELL'ULTIMO PAZIENTE |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 3 |